Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV Vaccine

Our first vaccine candidate, IVX-121, is being developed to protect older adults from respiratory syncytial virus (RSV) disease.

Icosavax is unlocking a whole class of challenging vaccine targets to improve human health.